Fri, Dec 26, 2014, 1:08 PM EST - U.S. Markets close in 2 hrs 52 mins

Recent

% | $
Quotes you view appear here for quick access.

NeuroMetrix Inc. Message Board

  • sfvictim sfvictim Nov 6, 2013 7:57 PM Flag

    There Are Several Reasons to Buy This Stock

    Shai Gozani is a brilliant biomedical engineer, but he has made several missteps with NURO in the past by hiring the wrong people. Seven years ago, this was a high flying stock. They aggressively sold a remote sensor device that could detect carpal tunnel nerve injury. While it was a useful diagnostic tool, the marketing director at the time appealed to primary care physicians' sense of larceny which gave them huge profits on the superbill for any patient who walked in the door. The neurologists, protecting their turf, went crazy and lobbied to get Medicare reimbursement reversed. Third party payers also dropped out and the Company had to pay a big fine that wrecked their balance sheet. The neurologists who made a big chunk of their money, fee for service doing painful EMG tests got to keep their business.
    Then NURO tried to sell direct to consumer the diabetic neuropathy diagnostic tests. They had no experience in selling to consumers and the test bombed. The Company still gets minimal legacy revenues from the aforementioned tests, but it doesn't bring them enough cash to keep operations going. During this period they went through several reverse splits.
    So if you bought the stock today for $2, it was once prior to reverse splits, worth about $300 per share.
    The technology for these devices, if they fall into the right salespeoples' hands, is still good.
    The device that everyone is excited about right now is their galvanic nerve stimulator. It's the only FDA approved device that can be used at night. This is a big deal because painful nights have a huge impact on quality of life. This device is a winner, but it's only starting to ramp. If they can sell it to other health professionals, who sell devices out of their offices, like chiros, podiatrists and cash hungry primary care physicians, it will gain traction against the competition. Market cap is still cheap. They already did a raise and a reverse split this year, and you're buying shares at the same price.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
NURO
1.76-0.02(-0.88%)12:52 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.